GSK Pays $321M For Swiss Vaccine Developer Okairos

By Jake Simpson
May 29, 2013, 2:47 PM EDT

GlaxoSmithKline PLC has acquired private Swiss vaccine developer Okairos AG from the company and its venture capital backers for €250 million ($321.4 million) in cash, the U.K. pharmaceutical giant said Wednesday. ...

Already a subscriber? Click here to view full article